GlassScriptPhysician profile
Alexander N Greiner
NPI 1609801299
$51,356.80
in general payments reported to CMS, 2019-2025
39 companies · $545 in 2025
The $545 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $923 · 2020: $266 · 2021: $2,325 · 2022: $3,441 · 2023: $2,474 · 2024: $41K · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Food and Beverage: $2,565 · Travel and Lodging: $1,364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,472.93 |
| Food and Beverage | $2,564.90 |
| Travel and Lodging | $1,363.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipla USA INC. | $40,472.93 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $3,566.37 | 2019-2025 | Breztri, Fasenra, Tezspire |
| Genentech USA, INC. | $1,917.04 | 2021-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $1,340.29 | 2019-2025 | |
| Glaxosmithkline, LLC. | $815.64 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $540.45 | 2019-2023 | |
| Genzyme Corporation | $443.93 | 2019-2025 | |
| Pfizer INC. | $296.28 | 2019-2025 | |
| Csl Behring | $191.10 | 2019-2024 | Hizentra |
| Teva Pharmaceuticals USA, INC. | $187.07 | 2019-2020 | |
| Optinose US, INC. | $182.60 | 2019-2023 | |
| Abbvie INC. | $161.87 | 2022-2024 | |
| Kaleo, INC. | $151.30 | 2019-2023 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $126.11 | 2020-2025 | Eohilia, Takhzyro, Cuvitru |
| Pharming Healthcare, INC. | $124.34 | 2022-2025 | Ruconest |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $114.00 | 2020-2024 | Xembify |
| Alk-Abello, INC | $107.44 | 2020-2023 | Ragwitek, Odactra, Grastek |
| Ars Pharmaceuticals Operations, INC. | $77.32 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $74.48 | 2022-2024 | Orladeyo |
| Shire North American Group INC | $68.05 | 2019 | |
| Ionis Pharmaceuticals, INC. | $62.27 | 2025 | Dawnzera |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.33 | 2019-2022 | |
| Octapharma USA, INC. | $47.21 | 2023-2024 | Cutaquig, Octagam Immune Globulin (Human) |
| Gc Biopharma USA, INC. | $37.95 | 2024-2025 | Alyglo, Alyglo |
| Phadia US INC. | $30.45 | 2020-2021 | |
| Hospira, INC. | $29.68 | 2022 | |
| Blueprint Medicines Corporation | $29.26 | 2024 | Ayvakit |
| Incyte Corporation | $25.88 | 2023 | Opzelura |
| Lilly USA, LLC | $23.50 | 2025 | Ebglyss |
| Leo Pharma INC. | $23.02 | 2024 | Adbry |
| Bio Products Laboratory USA, INC. | $17.41 | 2019 | |
| Merck Sharp & Dohme LLC | $17.23 | 2023 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Greiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.